- Home
- ACM vs RPRX Comparison
ACM vs RPRX Comparison
Compare ACM & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACM
- RPRX
- Stock Information
- Founded
- ACM 1980
- RPRX 1996
- Country
- ACM United States
- RPRX United States
- Employees
- ACM N/A
- RPRX N/A
- Industry
- ACM Military/Government/Technical
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- ACM Consumer Discretionary
- RPRX Health Care
- Exchange
- ACM Nasdaq
- RPRX Nasdaq
- Market Cap
- ACM 16.6B
- RPRX 15.6B
- IPO Year
- ACM 2007
- RPRX 2020
- Fundamental
- Price
- ACM $131.10
- RPRX $36.15
- Analyst Decision
- ACM Strong Buy
- RPRX Strong Buy
- Analyst Count
- ACM 10
- RPRX 4
- Target Price
- ACM $131.00
- RPRX $44.50
- AVG Volume (30 Days)
- ACM 1.0M
- RPRX 5.0M
- Earning Date
- ACM 11-17-2025
- RPRX 11-05-2025
- Dividend Yield
- ACM 0.79%
- RPRX 2.44%
- EPS Growth
- ACM 147.22
- RPRX 54.86
- EPS
- ACM 4.59
- RPRX 2.32
- Revenue
- ACM $16,074,699,000.00
- RPRX $2,305,243,000.00
- Revenue This Year
- ACM $2.09
- RPRX $35.14
- Revenue Next Year
- ACM $5.76
- RPRX $1.24
- P/E Ratio
- ACM $28.61
- RPRX $15.54
- Revenue Growth
- ACM 1.50
- RPRX 3.02
- 52 Week Low
- ACM $85.00
- RPRX $24.05
- 52 Week High
- ACM $133.81
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- ACM 57.22
- RPRX 51.84
- Support Level
- ACM $127.61
- RPRX $35.67
- Resistance Level
- ACM $131.46
- RPRX $36.48
- Average True Range (ATR)
- ACM 2.35
- RPRX 0.71
- MACD
- ACM -0.24
- RPRX 0.07
- Stochastic Oscillator
- ACM 52.77
- RPRX 71.37
About ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $16.1 billion in sales in fiscal 2024.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.